Mallinckrodt adopts 2025 equity plan; reserves 5.77M shares, approves CEO inducement RSU

Keenova Therapeutics plc

Board adopted 2025 Stock and Incentive Plan reserving 5,771,538 ordinary shares for equity awards.
Approved form of CEO RSU inducement award for CEO Olafsson per July 7, 2025 employment agreement.
Approved forms of RSU awards for executives and non-employee directors under the plan.
Plan has 10-year term, administered by Human Resources and Compensation Committee.
Awards subject to forfeiture and recoupment under company’s Executive Financial Recoupment Program.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.